BioMerieux and Banyan Biomarkers form new diagnostic alliance

BioMerieux has announced a new collaboration with Banyan Biomarkers, a company developing blood tests that could be used to diagnose traumatic brain injuries.

The agreement will see BioMerieux take an equity stake worth $7 million (5.61 million pounds) in Banyan, as well as obtaining the rights to commercialise its proprietary tests worldwide for use in in vitro diagnostics.

This deal will include preferred rights for the Vidas immunoassay range, with the two companies to continue to explore co-development opportunities in the area of traumatic brain injury and critical care in addition.

Combining Banyan's innovative biomarkers with BioMerieux's diagnostics expertise and global commercial footprint is expected to result in the first blood-based automated test for traumatic brain injury to earn US regulatory approval.

Francois Lacoste, corporate vice-president for BioMerieux's clinical unit, said: "This partnership with Banyan Biomarkers illustrates our commitment to bring pioneering high medical value diagnostic solutions to the physicians and help them improve patient care and reduce healthcare spending."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.